Drug Maker Will Soon Hold Patent On THC, CBD As Cancer Cures

GW Pharmaceuticals, a drug company that specializes in cannabis-based pharmaceuticals, has received early approval on a patent covering the use of marijuana chemicals for treating brain cancer.

GW Pharmaceuticals announced Wednesday that it has been issued a Notice of Allowance from the U.S. Patent Office for a patent application involving the use of THC and CBD, the two main chemicals in marijuana, for treating gliomas.

Once a patent application is deemed a genuine invention, the Patent Office sends a Notice of Allowance that outlines the fees involved with final approval.

Specifically, the company provides this description of the patent:

“The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume.”

Filed in 2009, GW’s patent application lists Otsuka Pharmaceutical as a collaborator and initially claimed the invention of the “use of a combination of cannabinoids in the manufacture of a medicament for use in the treatment of cancer.”

However, it’s likely that the application was revised since then to be more specific in its claims, including the ratio of THC to CBD used and the type of cancer treated.

Indeed, the use of cannabis and cannabis-derived chemicals to fight a wide range of cancers has long been suggested by pre-clinical research as well as anecdotal reports.

On the other hand, the first clinical trial to investigate these cancer treatments only began last month, launched by GW Pharmaceuticals for their cannabis drug Sativex.

The trial investigates Sativex in combination with the standard chemotherapy drug temozolomide, and involves 20 patients with recurrent glioblastoma multiforme (GBM), an aggressive and rare form of brain cancer.

GW Pharmaceuticals also announced in November that it had begun human trials of a CBD-rich cannabis drug for the treatment of pediatric epilepsy.

Oregon’s Elected Officials Show Leadership

by Keith Stroup, NORML Legal Counsel

For those of us who have spent years in the trenches of marijuana policy reform, it has been a rare sight to see elected leaders actually lead. It has been the voting public who have paved the way.

But there is a glimmer of hope in Oregon.

In the four states, and the District of Columbia, that have legalized marijuana in the face of federal prohibition, those courageous and innovative steps were taken by the voters, not the elected officials in those jurisdictions.

In fact, not only were most elected officials unwilling to seriously consider enacting legalization legislatively, most also publicly opposed the proposals and urged their defeat at the polls. Fortunately the voters led the way, and left their “leaders” to follow.

So we are accustomed to the challenge of moving progressive marijuana legislation forward despite the active opposition of most politicians. It means we mostly focus on those states that offer a voter initiative as a way to change public policy by going around the legislature. And it sometimes results in constitutional amendments being proposed, despite higher approval requirements in some states, to protect against the possibility that the legislature might simply ignore the will of the voters and reverse a legalization initiative by a vote of the out-of-touch legislators still holding on to their war-on-marijuana mentality.

But there are some new signs that this overwhelming opposition of elected officials to marijuana legalization may be coming to an end, at least in some states, and that some elected officials are now deciding to embrace these new changes and to take steps to implement them in a common-sense manner, to serve the public interest.

I am referring specifically to the recent decision of the Oregon legislature to begin offering legal recreational marijuana sales a year earlier than had been expected. They had no legal requirement to make this change, but they decided to accept the will of the voters and to implement the new law sooner rather than later. They acted like leaders, rather than sore losers.

SB 460 Approved by Legislature, Signed by Governor

Measure 91, the legalization initiative that was approved by 56 percent of Oregon voters in November of 2014, would have been implemented in two-steps. First, as of July 1, 2015, it became legal for those 21 and above to possess up to an ounce of marijuana, to possess up to 8 ounces in the home, and to privately cultivate up to four plants. But provisions in the initiative that gave the Oregon Liquor Control Commission the authority to begin issuing licenses for commercial growers and sellers, delayed this process until January 4, 2016, and legal dispensaries were not expected to be operational until October of 2016.

The result, like the current situation in the District of Columbia, is that recreational marijuana is now legal in Oregon, but there is no legal market. But unlike the District, where the City Council has been hamstrung by Congress in their efforts to establish licensed growers and sellers, the Oregon legislature decided to fix the problem with a short-term solution – they enacted emergency legislation allowing the existing 300-plus licensed medical marijuana dispensaries, which are regulated by the Oregon Health Authority, to begin selling to adult recreational smokers on October 1, 2015.

Recreational consumers will also be able to purchase marijuana seeds and up to four non-flowering plants. (In a nod to local control, counties that opposed Measure 91 with at least 55 percent of the vote, all located on the east side of the state, were given the right to ban recreational sales during this interim program.)

That’s right! The legislature enacted, and Gov. Kate Brown promptly signed, SB 460, bringing full legalization to Oregon a full year ahead of schedule. For once, instead of trying to undermine the new law, they have embraced it and elected to try to make it work as intended by the voters.

Gov. Brown’s office called the measure “a smart solution to a short-term logistical problem,” adding, “If marijuana is legal to use, it shouldn’t be illegal to buy.”

The new law will permit recreational users to purchase up to one-quarter of an ounce of marijuana per transaction from any of the licensed medical dispensaries. The Oregon Liquor Control Commission will continue forward with the process of issuing recreational licenses after the first of the year, and when those new recreational dispensaries are up and running, consumers will be permitted to purchase up to one ounce of marijuana per transaction.

A Model for Elected Officials Moving Forward

One admirable, common sense step by one state legislature does not make a trend, but it does establish a powerful example of how elected officials can get ahead of the curve and work cooperatively to implement these new laws, without delay, and one that can be the model for elected officials in the states that are expected to adopt legalization in the coming months.

A majority of the voters nationwide now support full legalization, and that support appears to be growing. They understand that prohibition is a failed public policy and legalization with regulation is a better option for everyone, smokers and non-smokers alike. When voters clearly register their approval for marijuana legalization, it’s time for the politicians to acknowledge that change, embrace it, and take steps to implement the new laws in a timely and responsible manner. It is time to lead, for a change.

This column first appeared @ marijuana.com.

CannaVest Closes $6,500,000 Financing With Institutional Investor and Restructures Commitments to Supplier

LAS VEGAS, NV–(Marketwired – May 26, 2015) – CannaVest Corp. (OTCQB: CANV), a leading manufacturer and distributor of hemp, cannabis derivative, and Cannabidiol (CBD) based products, today announced that it has closed a $6,500,000 financing with an institutional investor, which will provide CannaVest with additional working capital as it continues to rapidly expand its customer base and sales channel. As more particularly set forth in CannaVest’s Form 8-K filed with the Securities and Exchange Commission on May 21, 2015, the financing is structured in tranches, where CannaVest will receive four tranches of $500,000 each, and a final two tranches of $2.25 million upon the effectiveness of its registration statement to be filed with the SEC seeking to register the shares issuable under the financing.

CannaVest’s Chairman and Chief Executive Officer, Michael Mona, Jr., stated, “We very carefully selected our partner in this financing, and after talking with multiple investors interested in our company, we selected the investor willing to invest in our company’s fundamentals and bet on the future success of our operations. We believe the terms of the financing reflect this, by allowing us to confidently predict and control the number of shares issuable to the investor. Unlike many investors in small cap companies, our investor was willing to negotiate and agree on terms that will support our efforts to provide value to our stockholders.”

In addition to securing additional working capital through the financing, CannaVest also announces that it has successfully renegotiated its financial commitments to its leading supplier of raw material in Europe. “Maintaining our dominant supply chain position and the strong relationships with our suppliers is a key differentiating value component of our company,” stated Joseph Dowling, Chief Financial Officer of CannaVest. “We are fortunate that our leading supplier recognized that limiting our financial outlay in 2015 for securing new product would greatly enhance the long term strength of our company. By restructuring our 2015 commitment to our supplier, we are now able to dedicate our resources toward continuing to build our sales channel,” continued Mr. Dowling.

About CannaVest Corp.
CannaVest Corp. (CANV) is a leader in the procurement and wholesale of the hemp plant extract cannabidiol (CBD), and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand. CannaVest resells raw industrial hemp product to third parties, acquired through supply relationships in Europe. CannaVest has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cannavest.com.

CannaVest Corp.’s subsidiaries include CannaVest Laboratories, LLC, which facilitates leading research and develops nutraceutical and food products, containing cannabidiol (CBD) oil, and is the developer and manufacturer of CannaVest’s own award winning CBD Simple™, and US Hemp Oil, LLC, which provides seed procurement, cultivation, processing, and production consultation, and equipment to support U.S. farmers, researchers and businesses to cultivate and process industrial hemp in the U.S.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of CannaVest Corp. to be materially different from the statements made herein.

LEGAL DISCLOSURE
CannaVest Corp. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets.

GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) –

LONDON, Aug. 6, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE. In addition, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE, for which GW has already received Orphan Drug Designation from the FDA. There are currently no approved medicines in Europe or the U.S. specifically indicated for NHIE or perinatal asphyxia.

“GW believes that cannabinoids may have a potentially important role in the treatment of high need pediatric neurologic conditions. As a result, we have developed a proprietary intravenous CBD formulation specifically for use in this most vulnerable of patient populations, newborn infants with NHIE. As there are no current treatment options beyond induced hypothermia for the affected newborns, there exists a dramatic need to develop new and effective therapies aimed at preventing acute brain damage and enhancing long-term brain repair,” stated Justin Gover, GW’s Chief Executive Officer. “GW is now working towards the launch of a clinical development program in this important medical condition towards the end of this year.”

NHIE and perinatal asphyxia are forms of acute or sub-acute brain injury due to asphyxia caused during the birth process and resulting from deprivation of oxygen during birth (hypoxia). The incidence of these conditions is estimated to be approximately 12,000 to 24,000 cases per year in the United States and EU combined. Of these cases, 35% are expected to die in early life and 30% may suffer from permanent disability. The current standard of care for perinatal asphyxia patients is to induce whole-body hypothermia. This treatment is only available in specialized neonatal intensive care units and must be started within 6 hours of birth. Even if a patient is put into induced hypothermia there is still a significant rate of morbidity and mortality, with a meta-analysis of the available data revealing a 27% death rate. Among the patients who survive, 28% suffer from major neurodevelopment issues and 26% develop Cerebral Palsy.

FDA’s Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug’s development, review and potential approval to get important new drugs to the patient earlier.

The EMA orphan designation is a status assigned to a medicine intended for use against a rare condition (prevalence of the condition in the European Union must not be more than 5 in 10,000) and allows a pharmaceutical company to benefit from incentives offered by the EU to develop a medicine for the treatment, prevention or diagnosis of a disease that is life-threatening or a chronically debilitating rare disease. These incentives can include reduced fees and protection from competition once the medicine is placed on the market.

References:

Smith J, Wells L, Dodd K. The continuing fall in incidence of hypoxic Ischaemic encephalopathy in term infants. Br J Obstet Gynaecol 2000;107:461

Thornberg E, Thiringer J, Odeback A, Milsom I. Birth asphyxia: incidence, clinical course and outcome in a Swedish population. Acta Paediatr 1995;84:927

Ghi T, Giunchi S, Pilu G, Youssef A, Morselli-Labate AM, Arcangeli T, Meriggiola MC, Pelusi C, Ancora G, Cocchi G, Faldella G, Pelusi G. Neonatal hypoxic-ischemic encephalopathy in apparently low risk pregnancies: retrospective analysis of the last five years at the University of Bologna. J Matern Fetal Neonatal Med. 2010 Jun;23(6):516-21

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (CBD or cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding the therapeutic benefit, safety profile and commercial value of the company’s investigational drug candidate cannabidiol, the development and commercialization of cannabidiol, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®, Epidiolex®, and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
+44 20 3727 1000
Robert Stanislaro (U.S.)
212 850 5657

Article provided by Globe News Wire – http://globenewswire.com/news-release/2015/08/06/758426/10144937/en/GW-Pharmaceuticals-Receives-FDA-Fast-Track-and-EMA-Orphan-Designations-for-Intravenous-Cannabidiol-in-the-Treatment-of-Neonatal-Hypoxic-Ischemic-Encephalopathy-NHIE.html?f=22&fvtc=3&fvtv=4000#sthash.4uxStxhy.dpuf

Carbondale woman cultivating industrial hemp for seeds

By John Colson

Sopris Sun Staff Writer

The nascent Colorado hemp industry has gotten a double boost in recent months, with a federal decision that made it legal to import hemp seeds into the state for research purposes, and the production of thousands of pounds of seeds by the Colorado Hemp Project.

And here in Carbondale the industry is beginning to take root, as activists start growing their own plots of hemp with the plan of producing seeds for sale to other hopeful hemp farmers.

The news that hemp seed can now be imported into Colorado by entities engaged in official research projects was announced on May 11, in a story by KUNC public radio sin Greeley.

The story, by former Aspen Public Radio reporter Luke Runyon, revealed that the Colorado Department of Agriculture had received permission from the federal Drug Enforcement Administration to import industrial hemp seeds from other countries.

A year ago, Kentucky became the first state to get the same permission, after the state won a lawsuit against the DEA over its restrictions on the importation of hemp seeds.

The decision, Runyon reported, came after “months of wrangling” as federal authorities wrestled with the question of how to react to Colorado’s passage of Amendment 64, which legalized the recreational use of marijuana by those over 21 as well as the cultivation and use of marijuana’s non-psychoactive cousin, known as industrial hemp.

“The seeds are essential to kick-start Colorado’s hemp industry,” Runyon reported, “which state agriculture officials say has seen a bottleneck in research and cultivation due to a lack of viable seeds.”

He reported that most of the early shipments of seeds will go to researchers at Colorado State University and at the University of Colorado, where the seeds will be used “to grow more reliable seeds that farmers can plant in a certified seed program.”

In early May, a story in the Denver Business Journal reported that the Colorado Hemp Project in Sterling, Colorado, has produced 2,000 pounds of seeds from a 2.5-acre plot of land, and that the group is planning to expand production as quickly as possible in order to provide a viable source of seeds grown in the state rather than outside the U.S.

Meanwhile, back in Carbondale, a local woman confirmed to a reporter that she has planted her own crop of hemp in a backyard greenhouse, with the goal of producing seeds for others to use. The woman requested anonymity due to the plant’s illegality under federal law.

Hemp in this country largely has been bred to eliminate THC, or tetrahydrocannabinol, the chemical that get people high from smoking or ingesting its mind-altering cousin, marijuana.

Nevertheless, hemp has been classified as a Schedule 1 drug since 1957 by the DEA. That listing is primarily because federal drug agents were concerned they could not distinguish between hemp and marijuana in the field, according to numerous reports.

Currently, federal legislation is pending that would strip hemp of its drug classification and make it legal as an agricultural, industrial crop, thereby restoring the plant to its historic usefulness in making rope, paper, clothing, medicinal products, industrial lubricants and more.

 

Colorado Gold

The Carbondale resident, who is not alone in growing test plots of hemp locally, said she got her Colorado Gold seeds from a hemp grower in Boulder and planted two crops, one on April 4 and the second on May 4.

She said she has a state “ag license,” the necessary state permit to grow the crop, at a cost of $200.

She noted that “this particular strain is super-low in THC … less than .001 percent.” The government requires a concentration of THC below .3 percent in order for the cannabis plant to be considered “industrial hemp” rather than a mind-altering drug.

Already, the hemp planter told The Sopris Sun this week, the April 4 crop has been rendered “monecious,” or self-propagating, by the uprooting of all the male plants.

The remaining plants in the April crop are producing dense clusters of seeds, and she expects the May 4 planting to do the same.

She then hopes to sell the seeds, possibly for as much as $2 per seed. To do so, she said, she will need a separate license, at a cost of $75, to enable her to legally sell the seeds.

Another state law, she said, sets a minimum germination rate of 75 percent, meaning at least three out of four seeds will germinate and grow into plants. This crop, she said, has demonstrated a germination rate of 90 percent, meaning buyers of her seed can be fairly certain that almost all of the seeds will produce plants.

Our local hemp farmer has been told she should get 500 seeds from a single plant, but after watching the plants grow, she predicted, “That’s not going to happen.”

She expects her plants to be shorter and less productive than plants in other parts of Colorado, perhaps due to Carbondale’s altitude.

She said she also plans to have the stems processed to produce CBD, a non-psychoactive cannabinoid oil that has been shown to have numerous medicinal applications, including a reduction of seizures caused by certain diseases.

The woman said she has had a good experience dealing with state agencies that oversee hemp cultivation regulations in Colorado.

“It’s well regulated, and they are really, really helpful, because this (the growing hemp market) is a good thing,” she said of the bureaucrats she has worked with.

As she goes through the paces of growing and harvesting her plants, she said, “I’m keeping copious notes, because there really isn’t a lot of information out there about growing hemp at this altitude.”

The information she compiles, she hopes, will be beneficial to anyone interested in starting large-scale hemp cultivation operations on the Western Slope, which many see as a potential economic boon for regional ranchers having trouble keeping afloat in the struggling, traditional ranching economy.

Published in The Sopris Sun on June 18, 2015. 

http://www.soprissun.com/news-general/150618_hempseeds

Hemp Inc (OTCMKTS:HEMP) Hesitating Around The $0.015 Per Share Mark

This article provided by https://www.hotstocked.com/article/90866/hemp-inc-otcmkts-hemp-hesitating-around-the.html

The first half of the year went rather badly for the stock of Hemp Inc (OTCMKTS:HEMP, HEMP message board) as the stock lost more than 50% of the value it had in January. The recent news that North Carolina has approved the legalization of Hemp/CBD oil had an impressive on the company stock in the beginning of last week, but the hype quickly dissipated.

One of the reasons might be the fact that HEMP is still not fully operational. Their Temafa decortication plant is still not reassembled and the numbers contained in the company’s balance sheet for the first quarter of the year don’t look very appealing.

cash: $632 thousand
current assets: $2.3 million
current liabilities: $2.27 million
quarterly revenues: $6,223
quarterly net loss: $1.08 million

And while some investors might argue that the company’s cash reserves and current assets are decent we must not forget that the current market cap of HEMP is standing above $40 million. Considering the massive dilution that the company stock has experienced, the 2.5 BILLION increase in authorized shares and the impressive amount of preferred shares still not converted this valuation seems a bit steep.

These are all prerequisites for HEMP’s lack of ability to keep the gains it made after the NC legalization of CBD/Hemp oil. The company slipped 4.91% in yesterday’s session and closed at $0.0155 with a total of 10.3 million traded shares and a daily dollar volume of $167 thousand.

In any case, you should be sure to do your own due diligence and weigh out any risks involved before putting any money on the line.

Watch the video to learn about the probability of HEMP, INC. (HEMP) Chart Signal as of Aug 01, 2015

There Are More Marijuana Legalization Initiatives than GOP Presidential Candidates

This article provided by http://www.huffingtonpost.com/russ-belville/there-are-more-marijuana-_b_7867726.html?ir=India&adsSiteOverride=in
Not counting initiatives for industrial hemp or non-plant medical marijuana or low-THC cannabidiol oil, there are at least* 20 efforts going on in 8 states nationwide to legalize medical and recreational access to cannabis in 2016. As of this week, there are 16 Republican candidates running for president in 2016.
Arizona
Arizonans for Mindful Regulation (AZFMR) will legalize possession of an ounce of flowers and an ounce of concentrates, home cultivation of twelve mature plants per adult plus possession of the harvests, but landlords could prohibit cultivation on their properties. Localities could not ban home growing. Most marijuana crimes below a half-pound or 100 plants are reduced to misdemeanors. Marijuana metabolites in their urine can no longer be used to fire employees or convict DUIs. Marijuana will be taxed at 10 percent.

Campaign to Regulate Marijuana Like Alcohol (RegulateAZ) will legalize possession of an ounce of flowers and 5 grams of concentrates, home cultivation of six mature plants per adult and a max of 12 per household plus possession of the harvests, but landlords could prohibit cultivation on their properties and localities can ban home growing altogether. Marijuana will be taxed at 15 percent. The proposal is backed by the Marijuana Policy Project.

California
California Artisan Cannabis Initiative (CACI) places no limit on how much useable cannabis a person could possess, but does limit a personal garden to six cannabis plants. This initiative takes great care in providing for “craft cannabis” growers who are producing fewer than 100 plants.

California Bipartisan Decriminalization of Cannabis Act (CBDCA) proposes that adults 21 and older be allowed five pounds of marijuana, a pound of concentrate, and a 500 square foot personal garden. All medical dispensaries will become recreational shops with a 15 percent excise tax and localities could not ban them.

California Cannabis Hemp Initiative (CCHI) will allow adults to cultivate 99 mature plants and possess 12 pounds of useable marijuana, free non-violent marijuana prisoners, open up tax-free statewide access to medical marijuana, end workplace drug testing for marijuana metabolites, and establish industrial hemp production and commercial marijuana with a 10 percent cap on taxes.

Coalition for Cannabis Policy Reform (ReformCA) has not put forth initiative language yet, but has hired political consultants Joe Trippi and Jim Gonzalez, as well as the company Progressive Campaigns Inc. to handle the gathering of petition signatures. ReformCA is backed by or working with all the major national marijuana reform groups.

Community Restoration Act to Regulate, Control and Tax Cannabis (CRA) has been filed by Alice Huffman of the California NAACP. It may be more conservative than what ReformCA will propose, offering just one ounce of possession in public and a 25 square foot garden, from which adults may possess all their harvest at home.

Compassionate and Sensible Access Act (CSA) amends California medical marijuana law to end the practice of local bans on medical cultivation and dispensary access.

Marijuana Control, Legalization and Revenue Act (MCLR) seems to place no limit on how much cannabis one can possess and cultivate, leaving that to be determined by a Cannabis Control Commission set up by the initiative.

Responsible Use Act (RUA) will allow 1.5 pounds and 12 mature plants. Like CBDCA, RUA will make all medical dispensaries become recreational shops and forbid local bans, but the tax will be $8 per ounce plus up to a 2 percent local tax.

Right to Medical Marijuana Act (RMMA) adds a simple statement to the California Constitution that “any resident, having obtained the age of 18 years has the right to grow, own, purchase, and obtain a permit from the State to sell organic marijuana for medical use, without a licensed physician’s recommendation or prescription.”

Florida
People United for Medical Marijuana (PUFMM) is the second attempt by attorney John Morgan and the United for Care Campaign to place a constitutional amendment legalizing medical marijuana in the state of Florida. The 2014 effort got 58 percent of the vote, but needed 60 to win. The amendment will not allow patients to home grow, but will allow access to whole-plant medical marijuana.

Maine
Legalize Maine will legalize possession of 2.5 ounces and cultivation of 6 mature plants, 12 immature plants, and unlimited seedlings. The Dept. of Agriculture will regulate the commercial marijuana market, consisting of adult use social clubs and unlimited retail stores with preference given to medical marijuana caregivers and dispensaries, subject to a 10 percent flat sales tax.

Campaign to Regulate Marijuana Like Alcohol (RegulateME) will legalize possession of one ounce and cultivation of 6 plants. The Alcohol Bureau will regulate the commercial marijuana market, consisting of adult use social clubs and 70 initial retail stores run by a majority of Maine residents, subject to a 10 percent tax on top of standard sales tax. The proposal is backed by the Marijuana Policy Project.

Massachusetts
Bay State Repeal proposes to legalize marijuana farmer’s markets and cannabis cafés, and protects marijuana farmers and marijuana retailers from any restrictions not made on other farmers and alcohol retailers. Its marijuana laws will be made retroactive for people previously convicted of marijuana crimes, to help reduce fines and sentences. Personal possession and home cultivation are made legal with no specific limits.

Campaign to Regulate Marijuana Like Alcohol (RegulateMA) is backed by the Marijuana Policy Project, but has yet to disclose any details of their initiative.

Michigan
Comprehensive Cannabis Law Reform Initiative Committee (MILegalize) will allow cultivation of 12 plants over 12″ tall and unlimited plants under 12″ and possessing the results of the harvests. Gifting of up to 2.5 ounces to other adults is allowed. Commercial marijuana will be available and subject to a 10 percent tax.

Michigan Cannabis Coalition (MICannabis) will legalize home cultivation of marijuana with a maximum of two plants in flower, though localities could ban home cultivation or raise the limit to four flowering plants. Adults could share any of their homegrown marijuana with other adults. A commercial system of retail marijuana will exist with taxes yet to be determined.

Missouri
Show-Me Cannabis will legalize possession of 1 ounce of extracts, 12 ounces of flower, 16 ounces of edibles, 20 ounces of liquids, and cultivation of 6 marijuana plants. It will also establish a medical marijuana program and a commercial marijuana market. It will also provide a path for expungement of past marijuana criminal records.

Nevada
The only one in this list already on the ballot, Regulate Marijuana Like Alcohol (RegulateNV) will legalize possession of 1 ounce of flowers and an 1/8-ounce of concentrates and cultivation of 6 marijuana plants per adult with a max of 12 per household, and to possess the results of the harvests. There will be a commercial marijuana market with a 15 percent excise tax. The proposal is backed by the Marijuana Policy Project.

* I could not include every state with an activist group proposing a ballot initiative. I’ve limited the list to those with the greatest media coverage.

Follow Russ Belville on Twitter: www.twitter.com/RadicalRuss
MORE: Marijuana Elections 2016 Election 2016 Marijuana
Huffington Post India Rishi Kapoor Tweets Picture Of Himself With A Barely Recognisable Meenakshi Seshadri
Fair & Lovely on College Diaries 3 things you need to know before college
The Truth Plate 7 AWESOME WAYS TO KNOW YOUR SPOUSE BETTER
OZY The Amazing NBA Player Who Wasn’t

Medical marijuana biotechs join forces

This article provided byhttp://www.news.com.au/finance/business/australian-medical-marijuana-merger/story-e6frfkur-1227460074532
PHYTOTECH Medical and MMJ Bioscience have joined forces to become the first Australian-listed medical marijuana company to control pharmaceutical hemp from farm to pharmacy counter.
THE re-branded MMJ PhytoTech will control the complete supply chain from cultivation to distribution after Phytotech raised $4.8 million to buy MMJ Bioscience.
MMJ PhytoTech chief executive Andreas Gedeon said the merger made the company one of the only serious players in the medical marijuana market.
“If you don’t own the supply chain the company can’t exist because you can’t buy the cannabinoil compounds, it has to be sourced from plants,” he said.
The company will cultivate marijuana plants at its Canadian subsidiary, United Greeneries, with the aim of exporting extracted compounds to MMJ PhytoTech’s Swiss operation where it will be sold in pill form.
PhytoTech is one of the only producers of organically derived active pharmaceutical ingredients (APIs), such as cannabidiol (CBD), that makes medical marijuana products affective, Mr Gedeon said.
“Laws created internationally around the 1950’s banned different things,” he said.
“Almost by mistake some classified and regulated cannabis the plant but others only disallowed THC – the psychoactive ingredient that makes you high.
“Cannabidiol has the THC extracted, freeing it from some regulatory restrictions in parts the European Union.”
Mr Gedeon said the paper work to get the company’s CBD capsules, Sativol, approved as a food supplement took a year to complete while its Canadian operations stared down regulatory hurdles for a decade.
But the pot entrepreneurs stand to be handsomely rewarded for their pioneer efforts because organically derived compounds can sell for up to $350,000 a kilo.
“In the last week, we had a six-figure order,” Mr Gedeon told AAP.
The company has it sights set on expanding into Australia’s infant medical marijuana industry which was given a multi-million dollar cash injection by the NSW government.
PhytoTech last made headlines in February when its colourful co-founder and chief executive Ross Smith stepped down amid reports he threatened critics on stock market forum Hot Copper.
Share prices plunged 12 per cent after it was widely reported Mr Smith said he would visit the critics home with his personal Israeli special forces bodyguard.
Prior to his company listing on the ASX, Mr Smith said he aimed to be “the George Clooney of medical cannabis.”
Mr Gedeon confirmed Mr Smith had no active role within the newly merged company other than being a shareholder.
Phytotech shares closed 1.5 cents higher at 35.5 cents.

Few expected to apply for hemp registration

This article provided byhttp://thesheridanpress.com/?p=39669
Cassidy Belus
July 28, 2015
SHERIDAN — As Sheridan and Wyoming residents have the opportunity to apply for hemp extract registration cards, questions over similarities between hemp and marijuana arise. Cards will provide qualifying individuals with intractable epilepsy to treat their symptoms with hemp.

Coming from Cannabis Sativa — a plant typically used for industrial purposes — it carries only trace amount of Tetrahydro-cannabinol, the principal psychoactive ingredient in marijuana. Products being made from hemp must contain less than 0.3 percent THC in order to be legally sold in Wyoming.

Hemp products — such as ropes and fabrics — are manufactured from the male plant while medical and recreational uses of marijuana come from the female plant.

Kim Deti of the Wyoming Department of Health, said only 175 people will qualify for hemp cards and, likely, not everyone will pursue it.

“This is not something that people should expect to see a large amount of participation in,” she said.

In order to legally purchase hemp for treatment, individuals must be diagnosed with intractable epilepsy by a neurologist before filling out multiple forms on the WDH’s site. Additionally, any THC in hemp extract will be minute and not lead to psychoactive reactions like marijuana. Simply put, hemp extract is not a drug that can substituted for recreational marijuana.

It may, however, be a step toward the legalization of medical marijuana, said Health Center Executive Director Wendy Ongaro.

Like many other drugs coming from cannabinoids — such as marinol for treatment in HIV and cancer patients — there are medical benefits, Ongaro said. When not abused, these drugs are not very concerning. Ongaro said she is more worried about current issues with prescription drug abuse and overdose in Sheridan County than marijuana use.

During an infectious disease residency at Duke University, Ongaro said she saw the benefits of marinol for treating serious illnesses. Currently, she works with low-income and addicted patients. Marijuana has not been an issue with her clientele.

Although not concerned, as progression is made toward legalized medical marijuana Ongaro said she plans to watch for any abuse. Like many naturally occurring substances before — chewing coca leaves in Peru as opposed to the cocaine addiction the U.S. sees — addiction can spike when the compounds are altered. Intentional chemical changes to natural substances by pharmaceutical companies have a somewhat poor history of working out, Ongaro said. When the substance is purified and/or strengthened for effect, it can lead to higher demand among users.

“Anytime we have purified something that’s psychoactive it hasn’t gone well,” she said.

what is hemps current status in the united states

This article provided byhttps://www.leafly.com/news/headlines/what-is-hemps-current-status-in-the-united-states


After a century of prohibition, hemp is once again taking root in American soil. With the passing of the 2014 federal farm bill (section 7606), farmers in states with industrial hemp legislation are allowed to grow and harvest hemp in conjunction with their state departments of agriculture for research through pilot programs.

Kentucky, Colorado, and Vermont all planted small research crops in 2014. As these states plant for a second year, many others, including Tennessee and Oregon, have passed hemp legislation and are planting their inaugural round of hemp crops.

To date, 33 states and Puerto Rico have introduced pro-hemp legislation, and 24 states have defined industrial hemp as distinct from other strains of cannabis and removed barriers to its production.

In January of 2015, the Industrial Hemp Farming Act was introduced in the House and Senate, H.R. 525 and S. 134. If passed, all current restrictions on the cultivation of industrial hemp would be removed, along with its classification as a Schedule 1 controlled substance.

Industrial hemp is legal to grow in more than 30 countries. The United States is one of the few industrialized nations that does not currently allow the cultivation of hemp. Millions of dollars worth of hemp is imported into the United States each year in order to fulfill the growing demand for hemp products. The annual retail sales for hemp products was estimated at $620 million in 2014. Much of it is being sourced from Canada, China, and other countries.

Some states have included market development in their hemp legislation, which allows farmers to profit from their crops and for products to be sourced from American-grown hemp. If the Hemp Farming Act passes, the hemp market would be allowed to flourish without intervention from the federal government. American farmers deserve the right to grow and profit from hemp once more, don’t you think?